longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

FOSUN PHARMA

02196

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 11.64, below the reasonable range, cheaper than 87.62% of the time in the past 5 years, and the industry ranks 13/52, the industry Median 7.21.

11.64xP/E
HK$17.12Stock price
HK$1.47Earnings per share
11.64xP/E
Stock priceHK$17.12Earnings per shareHK$1.47

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
14.91x
Typical range
12.14x–16.50x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 7.21x
010203040

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 7.21x
0x20x40x60x80x100x
P/E ratio
Name/Symbol
01093HKCSPC PHARMA
11.94x132.34%HK$102.15B
02196HKFOSUN PHARMA
11.64x19.55%HK$45.45B
02096HKSIMCERE PHARMA
16.17x33.45%HK$29.25B
00867HKCMS
15.33x40.18%HK$27.08B
00512HKGRANDPHARMA
15.62x45.32%HK$17.32B
02005HKSSY GROUP
15.05x24.61%HK$7.64B
00460HKSIHUAN PHARM
19.28x322.92%HK$6.70B
03613HKTONGRENTANGCM
13.71x26.60%HK$4.94B
01666HKTONG REN TANG
11.42x18.02%HK$4.03B
00719HKSHANDONG XINHUA
15.46x--HK$3.83B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.